About 300 reports

Filgrastim – Introduction ##.

  • Biological Therapy
  • Biotechnology
  • Filgrastim
  • World
  • Demand
  • filgrastim
  • filgrastim
  • Biotechnology
  • Asia
  • Japan
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • Chemotherapy
  • Therapy
  • Coherus BioSciences, Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • filgrastim - Drug Profile
  • Biocon Limited - Early Stage Pipeline Products
  • Biotechnology
  • India
  • World
  • Product Initiative
  • Biocon Limited
  • Filgrastim: Biosimilar Products in South Korea
  • Filgrastim: Biosimilar Products in China & Taiwan - 1/2
  • Biotechnology
  • Filgrastim
  • Europe
  • United States
  • Amgen Inc.
  • ZARXIO: PARAMETERS TO TEST SIMILARITY
  • ZARXIO: OVERVIEW
  • Biosimilar
  • Biotechnology
  • World
  • Market Size
  • Remicade group
  • PFIZER INC. - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • AUSTRALIA: BIOSIMILAR MEDICINES APPROVED AND LISTED ON THE PHARMACEUTICAL BENEFITS SCHEME
  • Biotechnology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • FILGRASTIM - DRUG PROFILE
  • FEBRILE NEUTROPENIA - PIPELINE BY BIOGENOMICS LIMITED, H1 2016
  • Biotechnology
  • Therapy
  • United States
  • World
  • Product Initiative
  • Strength 1 Low; 5 High
  • First biosimilar approved in Americas
  • Biotechnology
  • Europe
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biotech
  • Biotechnology
  • Chemotherapy
  • Filgrastim
  • Pharmaceutical
  • LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016
  • BIOSIMILAR RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • Biosimilar
  • Biotechnology
  • World
  • Market Size
  • Sandoz Inc.

Biosimilar G-CSF Submarket Outlook, 2016-2027 ##. ## Amgen Leads the Branded Biologic G-CSF Market ##. ## Teva Launches Long-Acting Pegfilgrastim ##. ## Selected Filgrastim Biosimilars Approved Worldwide ##. ##. ## The European G-CSF Biosimilars Market ##. ##. ##. ## Trends in Biosimilar Uptake Across Euro

  • Biosimilar
  • Biotechnology
  • Europe
  • World
  • Market Size
  • Biosimilars approved by PMDA in Japan
  • Assumptions
  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.
  • FILGRASTIM
  • FILGRASTIM - DRUG PROFILE
  • Biotech
  • Biotechnology
  • Chemotherapy
  • United States
  • Product Initiative

Filgrastim) Market Analysis, by Region, 2013-2022 ($MN) Table ## Global Human Growth Hormone (HGH) Market Analysis, by Region, 2013-2022 ($MN) Table ## Global Insulin Market Analysis, by Region, 2013-2022 ($MN) Table ## Global Interferons Market Analysis, by Region, 2013-2022 ($MN) Table ## Gl

  • Biotechnology
  • Asia
  • Europe
  • North America
  • World
  • filgrastim alone or in combination has the highest number of neutropenia ongoing clinical trials.
  • Clinical Trial profile. 13 Trial Title
  • Biotechnology
  • Blood Disease
  • World
  • Product Initiative
  • Amgen Inc.

Dosage strength comparison of Filgrastim BS vs.

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Japan
  • US Approved Biosimilars
  • 2.3 Overview of Biosimilars
  • Biotechnology
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Clinical Trial profile. 278 Trial Title
  • Target
  • Anti-Infective
  • Biotechnology
  • Blood Disease
  • Blood Supply
  • Clinical Trial
  • Target
  • Clinical Trial profile. 37 Trial Title
  • Biotechnology
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • 6.3 RECOMBINANT GROWTH FACTOR
  • Financial Overview (in EUR million)

It has received approval for tbo-filgrastim (XM## filgrastim).

  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.
  • JAN 27, 2017: WITHDRAWAL OF THE MARKETING AUTHORISATION APPLICATION FOR ZIOXTENZO (PEGFILGRASTIM)
  • JUN 13, 2017: US SUPREME COURT RULES IN FAVOR OF SANDOZ IN BIOSIMILARS CASE, ENABLING EARLIER ACCESS TO POTENTIALLY LIFE-SAVING MEDICINES

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Biotechnology
  • GlobalData's company
  • Nipro Corporation
  • Novartis AG
  • Sandoz Inc.
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY BIOGENOMICS LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC
  • Biotechnology
  • Chemotherapy
  • Gastrointestinal Drug
  • Neurological Disorder
  • Pharmaceutical
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
  • Biotechnology
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • Clinical Trial profile. 7 Trial Title
  • Therapy Area Indication(s)
  • Biotechnology
  • Clinical Trial
  • Leukemia
  • Lymphoma
  • Monoclonal Antibody

filgrastim Biosimilar Accofil Cadila Launches adalimumab Biosimilar EPIRUS Biopharmaceuticals Launches infliximab Biosimilar Celltrion Receives Japan' s MHLW Approval for Remsima Cipla Launches Biosimilar Darbepoetin alfa Under Actorise Brand Celltrion Announces Approval of biosimilar m

  • Biosimilar
  • Biotechnology
  • Europe
  • United States
  • World
  • FILGRASTIM - DRUG PROFILE
  • Biotechnology
  • Pathology
  • Pharmaceutical
  • Stroke
  • Therapy
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
  • Biotechnology
  • Blood Supply
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.